Cochlear Ltd
ASX:COH
Cochlear Ltd
Common Stock
Cochlear Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cochlear Ltd
ASX:COH
|
Common Stock
AU$1.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
44%
|
CAGR 10-Years
23%
|
|
|
Somnomed Ltd
ASX:SOM
|
Common Stock
AU$110.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Common Stock
AU$87.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
22%
|
CAGR 10-Years
19%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Common Stock
AU$88.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Common Stock
AU$54.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Common Stock
AU$41.8m
|
CAGR 3-Years
22%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Cochlear Ltd
Glance View
Cochlear Ltd., the renowned medical device company, traces its roots back to the vibrant medical innovation scene of Australia in the 1980s. Born from the pioneering research of Professor Graeme Clark, who was driven by a personal mission to help the hearing-impaired, Cochlear embarked on a journey that redefined the possibilities for those living with hearing loss. Over the years, the company has evolved into a global leader in implantable hearing solutions, headlined by its flagship cochlear implants. These intricate devices bypass damaged portions of the ear, directly stimulating the auditory nerve to restore the sense of hearing, thus providing users with the ability to connect more profoundly with the world around them. As scientific research advanced, so did Cochlear, developing a range of complementary products tailored to different degrees and types of hearing impairment. In a business model built on innovation and patient support, Cochlear generates revenue by designing, manufacturing, and marketing a portfolio of hearing implant products and related services. The company's value proposition lies not only in the initial sale of these high-tech devices but also in the ongoing customer relationships through upgrades, accessories, and maintenance services. By investing significantly in research and development, Cochlear ensures continuous improvement and the introduction of new solutions that meet the evolving needs of patients and healthcare providers. Their ability to offer comprehensive post-implantation support, such as rehabilitation services and patient care programs, strengthens customer loyalty and establishes recurring revenue streams, enabling Cochlear to maintain its competitive edge in the global market.
See Also
What is Cochlear Ltd's Common Stock?
Common Stock
1.2B
AUD
Based on the financial report for Dec 31, 2024, Cochlear Ltd's Common Stock amounts to 1.2B AUD.
What is Cochlear Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
23%
Over the last year, the Common Stock growth was -2%. The average annual Common Stock growth rates for Cochlear Ltd have been -2% over the past three years , 44% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet